Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 2/20 | 0.52 |
| ▸ | ME1 | P48163 | 2/20 | 0.52 |
| ▸ | ME3 | Q16798 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377866 | 0.87 | TSHR (0.55) | ME2ME1ME3NPC1TDP1 | |
| SCHEMBL2377039 | 0.84 | OPRD1 (0.56) | NPC1TDP1TSHRPOLBKDM1A | |
| SCHEMBL3896838 | 0.84 | NPC1 (0.50) | ME2ME1ME3NPC1TDP1 | |
| SCHEMBL31512422 | 0.84 | TSHR (0.66) | ME2ME1ME3NPC1TDP1 | |
| SCHEMBL10163014 | 0.83 | NPC1 (0.73) | ME2ME1ME3NPC1TDP1 | |
| SCHEMBL8326447 | 0.82 | SIGMAR1 (0.66) | KMT2AFKBP1AGAA | |
| SCHEMBL3155351 | 0.81 | SIGMAR1 (0.58) | NPC1POLBL3MBTL1KMT2A | |
| SCHEMBL9346536 | 0.81 | IAPP (0.53) | NPC1TDP1TSHRKMT2A | |
| SCHEMBL31512450 | 0.81 | ALDH1A1 (0.58) | ME2ME1ME3TSHRPOLB | |
| SCHEMBL31512444 | 0.81 | LMNA (0.60) | POLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | ME2 2779/4885ME1 2673/4885ME3 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.